EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Compartment-specific immune and tumor markers associated with clinical outcomes in patients with and without sarcomatoid/rhabdoid renal cell carcinoma treated with ipilimumab and nivolumab

N Savion-Gaiger, O Perales, D G Su, D Bar-Ziv, P Challa, D Djureinovic, I Yi, A Adeniran, H Kluger, D Schoenfeld

ESMO Open · 2026-05 · 11 (5) · 106908

DOI: 10.1016/j.esmoop.2026.106908 ↗

Kurz gefasst

Fachartikel in der Zeitschrift ESMO Open, 2026-05. Verfasst von N Savion-Gaiger und 9 weiteren Autor:innen. Beteiligte Einrichtung: Yale Cancer Center, Yale School of Medicine, New Haven, USA. Hauptthemen laut MEDLINE: Carcinoma, Renal Cell, Biomarkers, Tumor, Kidney Neoplasms, Ipilimumab. Die Arbeit nennt 55 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Yale University, US Department of Defense, NIH.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Renal CellBiomarkers, TumorKidney NeoplasmsIpilimumabNivolumabHumansFemaleMaleMiddle AgedAgedTumor Microenvironment

Stichwörter der Autor:innen

ICIsRCCmolecular biomarkersproteomicssarcomatoid/rhabdoid

Substanzen

Biomarkers, TumorIpilimumabNivolumab

Autor:innen und Institutionen

  • Yale Cancer Center, Yale School of Medicine, New Haven, USA.
  • Yale Cancer Center, Yale School of Medicine, New Haven, USA; Department of Surgery, Yale New Haven Hospital, New Haven, USA.
  • Department of Pathology, Yale School of Medicine, New Haven, USA.
  • Yale Cancer Center, Yale School of Medicine, New Haven, USA; Department of Medicine (Medical Oncology), Yale University School of Medicine, New Haven, USA. Electronic address: harriet.kluger@yale.edu.
  • Yale Cancer Center, Yale School of Medicine, New Haven, USA; Department of Medicine (Medical Oncology), Yale University School of Medicine, New Haven, USA. Electronic address: david.schoenfeld@yale.edu.

Förderung

  • Yale University
  • US Department of Defense
  • NIH

Zitieren

APA

Savion-Gaiger, N., Perales, O., Su, D. G., Bar-Ziv, D., Challa, P., Djureinovic, D., Yi, I., Adeniran, A., Kluger, H., & Schoenfeld, D. (2026). Compartment-specific immune and tumor markers associated with clinical outcomes in patients with and without sarcomatoid/rhabdoid renal cell carcinoma treated with ipilimumab and nivolumab. ESMO Open, 11(5), 106908. https://doi.org/10.1016/j.esmoop.2026.106908

Vancouver

Savion-Gaiger N, Perales O, Su DG, Bar-Ziv D, Challa P, Djureinovic D, et al. Compartment-specific immune and tumor markers associated with clinical outcomes in patients with and without sarcomatoid/rhabdoid renal cell carcinoma treated with ipilimumab and nivolumab. ESMO Open. 2026;11(5):106908. doi:10.1016/j.esmoop.2026.106908

BibTeX
@article{SavionGaiger2026,
  author = {Savion-Gaiger, N and Perales, O and Su, D G and Bar-Ziv, D and Challa, P and Djureinovic, D and Yi, I and Adeniran, A and Kluger, H and Schoenfeld, D},
  title = {Compartment-specific immune and tumor markers associated with clinical outcomes in patients with and without sarcomatoid/rhabdoid renal cell carcinoma treated with ipilimumab and nivolumab},
  journal = {ESMO Open},
  year = {2026},
  volume = {11},
  number = {5},
  pages = {106908},
  doi = {10.1016/j.esmoop.2026.106908}
}
Kostenlos starten →